JP4896959B2 - ドキソルビシン免疫測定法 - Google Patents

ドキソルビシン免疫測定法 Download PDF

Info

Publication number
JP4896959B2
JP4896959B2 JP2008504212A JP2008504212A JP4896959B2 JP 4896959 B2 JP4896959 B2 JP 4896959B2 JP 2008504212 A JP2008504212 A JP 2008504212A JP 2008504212 A JP2008504212 A JP 2008504212A JP 4896959 B2 JP4896959 B2 JP 4896959B2
Authority
JP
Japan
Prior art keywords
doxorubicin
general formula
compound
antibody
immunoassay method
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008504212A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008537110A (ja
JP2008537110A5 (enExample
Inventor
サルヴァトーレ サラモネ
ジョディ ブレーク コートニー
シュウ へ
Original Assignee
サラダックス バイオメディカル インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サラダックス バイオメディカル インク． filed Critical サラダックス バイオメディカル インク．
Publication of JP2008537110A publication Critical patent/JP2008537110A/ja
Publication of JP2008537110A5 publication Critical patent/JP2008537110A5/ja
Application granted granted Critical
Publication of JP4896959B2 publication Critical patent/JP4896959B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9446—Antibacterials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/807—Hapten conjugated with peptide or protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2008504212A 2005-03-30 2006-03-27 ドキソルビシン免疫測定法 Expired - Fee Related JP4896959B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66628805P 2005-03-30 2005-03-30
US60/666,288 2005-03-30
PCT/US2006/011022 WO2006104970A1 (en) 2005-03-30 2006-03-27 Doxorubicin immunoassay

Publications (3)

Publication Number Publication Date
JP2008537110A JP2008537110A (ja) 2008-09-11
JP2008537110A5 JP2008537110A5 (enExample) 2009-05-21
JP4896959B2 true JP4896959B2 (ja) 2012-03-14

Family

ID=37053697

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008504212A Expired - Fee Related JP4896959B2 (ja) 2005-03-30 2006-03-27 ドキソルビシン免疫測定法

Country Status (9)

Country Link
US (5) US7569358B2 (enExample)
EP (2) EP2239573A3 (enExample)
JP (1) JP4896959B2 (enExample)
AT (1) ATE476655T1 (enExample)
CA (1) CA2602849C (enExample)
DE (1) DE602006015929D1 (enExample)
DK (1) DK1864129T3 (enExample)
ES (1) ES2353212T3 (enExample)
WO (1) WO2006104970A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2602849C (en) * 2005-03-30 2013-06-04 Saladax Biomedical Inc. Doxorubicin immunoassay
US8076097B2 (en) * 2009-08-19 2011-12-13 Saladax Biomedical Inc. Imatinib immunoassay
US20110165699A1 (en) * 2009-12-08 2011-07-07 Salamone Salvatore J Irinotecan immunoassay
US20110136253A1 (en) * 2009-12-08 2011-06-09 Salamone Salvatore J Irinotecan Immunoassay
US8114621B2 (en) * 2010-03-12 2012-02-14 Saladax Biomedical Inc. Lenalidomide and thalidomide immunoassays
US8088594B2 (en) * 2010-03-16 2012-01-03 Saladax Biomedical Inc. Risperidone immunoassay
WO2012067670A1 (en) * 2010-11-18 2012-05-24 Saladax Biomedical Inc. Irinotecan immunoassay
US8426143B2 (en) 2011-05-24 2013-04-23 Saladax Biomedical Inc. Gemcitabine immunoassay
US8771972B2 (en) * 2011-05-24 2014-07-08 Saladax Biomedical Inc. Clozapine immunoassay
US20120301973A1 (en) * 2011-05-24 2012-11-29 Salamone Salvatore J Clozapine immunoassay
WO2012167255A1 (en) * 2011-06-03 2012-12-06 The Regents Of The University Of Colorado, A Body Corporate Anticancer prodrug therapies
US10782308B2 (en) 2012-07-16 2020-09-22 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Direct reading detection kits for surface contamination by antineoplastic drugs
EP2922818B1 (en) 2012-11-24 2018-09-05 Hangzhou Dac Biotech Co., Ltd Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
AU2014384434B2 (en) 2014-02-28 2016-11-03 Hangzhou Dac Biotech Co., Ltd Charged linkers and their uses for conjugation
WO2016026916A2 (en) * 2014-08-19 2016-02-25 Ecole Polytechnique Federale De Lausanne (Epfl) Phase transfer based chemical sensing
NZ739830A (en) 2015-07-12 2021-12-24 Hangzhou Dac Biotech Co Ltd Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
KR102345175B1 (ko) 2016-11-14 2021-12-31 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
CN114149474B (zh) * 2020-09-08 2024-03-19 鲁南制药集团股份有限公司 一种4’-表柔红霉素的中间体化合物及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07223969A (ja) * 1994-01-27 1995-08-22 Bristol Myers Squibb Co チオエーテル結合体の製造法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3996344A (en) 1972-05-15 1976-12-07 Biological Developments, Inc. Phenethylamine antigenic conjugates, their preparation, antibodies and use
US4016146A (en) 1974-12-10 1977-04-05 Biological Developments, Inc. Phenethylamine antigenic conjugates, their preparation, antibodies, and use
US4269511A (en) 1979-02-15 1981-05-26 Abbott Laboratories Apparatus and method for measuring the magnitude of polarization of light
US4420568A (en) 1980-07-30 1983-12-13 Abbott Laboratories Fluorescent polarization immunoassay utilizing substituted triazinylaminofluoresceins
IT1223136B (it) * 1987-11-17 1990-09-12 Ist Naz Stud Cura Dei Tumori Anticorpi monoclonali capaci di legarsi selettivamente alla doxorubicina ed analoghi e derivati
US4990443A (en) * 1988-01-25 1991-02-05 Boehringer Mannheim Gmbh Hapten-protein conjugates and methods of use in immunoassays
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Acylhydrazone derivatives of anthracycline and methods for their preparation
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5101015A (en) 1989-04-10 1992-03-31 Abbott Laboratories Reagents for an amphetamine-class fluorescence polarization immunoassay
IT1238675B (it) 1990-01-26 1993-09-01 Ist Naz Stud Cura Dei Tumori Anticorpo monoclonale in grado di riconoscere uno specifico epitopo di glicosidi antraciclinici e ibridoma secernente tale anticorpo
US5622929A (en) * 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
CA2096495C (en) 1992-06-16 2002-07-09 Kathy Palmer Ordonez Dual analyte immunoassay
US20020119095A1 (en) * 1992-07-10 2002-08-29 Reinhard Gabathuler Chemotherapeutic agents conjugated to p97 and their methods of use in treating neurological tumours
AU670108B2 (en) * 1992-09-11 1996-07-04 Becton Dickinson & Company Improved antibodies to plasmodium falciparum
DE4236237A1 (de) 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
DK0871490T3 (da) * 1995-12-22 2003-07-07 Bristol Myers Squibb Co Forgrenede hydrazonlinkere
WO2002013843A2 (en) * 2000-08-17 2002-02-21 University Of British Columbia Chemotherapeutic agents conjugated to p97 and their methods of use in treating neurological tumours
US7678551B2 (en) * 2004-10-25 2010-03-16 Seradyn, Inc. Immunoassays for lamotrigine
CA2602849C (en) * 2005-03-30 2013-06-04 Saladax Biomedical Inc. Doxorubicin immunoassay

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07223969A (ja) * 1994-01-27 1995-08-22 Bristol Myers Squibb Co チオエーテル結合体の製造法

Also Published As

Publication number Publication date
EP2239573A3 (en) 2011-02-08
JP2008537110A (ja) 2008-09-11
EP1864129A1 (en) 2007-12-12
US20120214184A1 (en) 2012-08-23
CA2602849A1 (en) 2006-10-05
US8053205B2 (en) 2011-11-08
US20090215078A1 (en) 2009-08-27
CA2602849C (en) 2013-06-04
EP2239573A2 (en) 2010-10-13
DK1864129T3 (da) 2010-11-29
ES2353212T3 (es) 2011-02-28
EP1864129A4 (en) 2009-02-18
US20060223134A1 (en) 2006-10-05
DE602006015929D1 (de) 2010-09-16
US7569358B2 (en) 2009-08-04
EP1864129B1 (en) 2010-08-04
US20120015385A1 (en) 2012-01-19
ATE476655T1 (de) 2010-08-15
WO2006104970A1 (en) 2006-10-05
US20090215082A1 (en) 2009-08-27
US8084586B2 (en) 2011-12-27

Similar Documents

Publication Publication Date Title
US8084586B2 (en) Doxorubicin immunoassay
JP5031585B2 (ja) ５−フルオロ−ウラシル免疫測定法
US20080287658A1 (en) Docetaxel Immunoassay
JP2011007807A (ja) タキソールの免疫学的検定
JP2010189414A (ja) サイトキサン抗体及びイムノアッセイ
US20060099665A1 (en) Taxol immunoassay
US20120302740A1 (en) Vincristine immunoassay
US8946392B2 (en) Gemcitabine immunoassay
HK1156108A (en) Docetaxel conjugates and immunogens for use in an immunoassay
HK1116250B (en) Docetaxel immunoassay
HK1156107A (en) Docetaxel conjugates and immunogens for use in an immunoassay

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090327

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090327

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20110127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110502

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110512

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110602

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110701

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110801

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111206

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111221

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150106

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees